Criteria for TNF-targeted therapy in rheumatoid arthritis estimates of the number of patients potentially eligible

Drugs

Volumn 61, Issue 12, 2001, Pages 1711-1720

  Kvien, T K ^a   Uhlig, T ^a   Kristiansen, I S ^b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG COST; ECONOMIC ASPECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

EID: 0034781112     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161120-00003     Document Type: Review

References (44)

1. What is the natural history of rheumatoid arthritis?
2. The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up
3. Functional impairment and disability in early rheumatoid arthritis - Development over 5 years
4. More evidence from a community based series of better outcome in rheumatoid arthritis. Data on the effect of multidisciplinary care on the retention of functional ability
5. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
6. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
7. Infliximab and methotrexate in the treatment of rheumatoid arthritis
8. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
9. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
10. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey
11. DC-ART: Preventing or significantly decreasing the rate of progression of structural joint damage
12. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 Year follow up of a prospective double blind placebo controlled study
13. DC-ART classification: Review of relevant clinical studies
14. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study
15. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
16. Progression in early erosive rheumatoid arthritis: 12 Month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate
17. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo
18. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis
19. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
20. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis
21. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
22. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
23. Outcome in rheumatoid arthritis. A 1985 inception cohort study
24. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
25. Rheumatoid arthritis: Not yet curable with early intensive therapy
26. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
27. Etanercept in children with polyarticular juvenile rheumatoid arthritis
28. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
29. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
30. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
31. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
32. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
33. Consistent improvement in radiographic joint damage in patients with active rheumatoid arthritis treated with infliximab along with methotrexate
34. Access to disease modifying treatments for rheumatoid arthritis patients
35. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
36. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis
37. The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway
38. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
39. The validity of self-reported diagnosis of rheumatoid arthritis: Results from a population survey followed by clinical examinations
40. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis
41. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
42. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis
43. What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations, or clinical protocols?
44. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab